BACKGROUND: Recent studies have suggested that a restrictive pattern assessed with a single spirometric test is associated with increased morbidity and mortality. This study was undertaken to determine demographic, clinical and mortality profiles of subjects with either a recurrent or an inconsistent restrictive spirometric pattern assessed prospectively. METHODS: Data from 2048 adult participants in the population-based TESAOD study were analysed. Normal (forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) ratio >or=70% and FVC >or=80% predicted), restrictive (FEV(1)/FVC >or=70% and FVC <80% predicted) and obstructive (FEV(1)/FVC <70%) patterns were assessed at the enrollment survey in 1972 and in 11 subsequent follow-up surveys up to 1996. Demographic and clinical characteristics were measured at enrollment and vital status and cause of death were assessed at January 2005. RESULTS: Overall, 12% of participants had a restrictive spirometric pattern at enrollment. They were less likely to be male, to smoke and to have asthma, and had lower IgE levels than subjects in the obstructive group. Among subjects with a restrictive pattern at enrollment, 38% developed an obstructive pattern during follow-up. The remaining 62% had either a recurrent (restrictive pattern >or=50% of follow-up surveys) or inconsistent (restrictive pattern <50% of follow-up surveys) longitudinal restrictive pattern. The recurrent and inconsistent restrictive groups had increased mortality risk for all-cause (adjusted HR 1.7 (95% CI 1.3 to 2.3) and 1.9 (95% CI 1.4 to 2.6), respectively), heart disease (2.0 (95% CI 1.3 to 3.1) and 2.7 (95% CI 1.7 to 4.3)), stroke (2.4 (95% CI 0.9 to 6.3) and 3.5 (95% CI 1.2 to 9.8)) and diabetes (8.0 (95% CI 2.9 to 21.8) and 6.0 (95% CI 1.9 to 19.2)). CONCLUSIONS: The restrictive spirometric pattern identifies a pulmonary condition that is distinguishable from obstructive lung disease and is associated with an increased risk of life-threatening comorbidities.
BACKGROUND:n class="Gene">Recent studies have suggested that a restrictive pattern assessed with a single spirometric test is associated with increased morbidity and mortality. This study was undertaken to determine demographic, clinical and mortality profiles of subjects with either a recurrent or an inconsistent restrictive spirometric pattern assessed prospectively. METHODS: Data from 2048 adult participants in the population-based TESAOD study were analysed. Normal (forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) ratio >or=70% and FVC >or=80% predicted), restrictive (FEV(1)/FVC >or=70% and FVC <80% predicted) and obstructive (FEV(1)/FVC <70%) patterns were assessed at the enrollment survey in 1972 and in 11 subsequent follow-up surveys up to 1996. Demographic and clinical characteristics were measured at enrollment and vital status and cause of death were assessed at January 2005. RESULTS: Overall, 12% of participants had a restrictive spirometric pattern at enrollment. They were less likely to be male, to smoke and to have asthma, and had lower IgE levels than subjects in the obstructive group. Among subjects with a restrictive pattern at enrollment, 38% developed an obstructive pattern during follow-up. The remaining 62% had either a recurrent (restrictive pattern >or=50% of follow-up surveys) or inconsistent (restrictive pattern <50% of follow-up surveys) longitudinal restrictive pattern. The recurrent and inconsistent restrictive groups had increased mortality risk for all-cause (adjusted HR 1.7 (95% CI 1.3 to 2.3) and 1.9 (95% CI 1.4 to 2.6), respectively), heart disease (2.0 (95% CI 1.3 to 3.1) and 2.7 (95% CI 1.7 to 4.3)), stroke (2.4 (95% CI 0.9 to 6.3) and 3.5 (95% CI 1.2 to 9.8)) and diabetes (8.0 (95% CI 2.9 to 21.8) and 6.0 (95% CI 1.9 to 19.2)). CONCLUSIONS: The restrictive spirometric pattern identifies a pulmonary condition that is distinguishable from obstructive lung disease and is associated with an increased risk of life-threatening comorbidities.
Authors: Emily S Wan; John E Hokanson; James R Murphy; Elizabeth A Regan; Barry J Make; David A Lynch; James D Crapo; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: William W Stringer; Janos Porszasz; Surya P Bhatt; Meredith C McCormack; Barry J Make; Richard Casaburi Journal: Chronic Obstr Pulm Dis Date: 2019-07-24
Authors: Monica M Vasquez; Muhan Zhou; Chengcheng Hu; Fernando D Martinez; Stefano Guerra Journal: Am J Respir Crit Care Med Date: 2017-05-15 Impact factor: 21.405
Authors: Andrei Schwartz; Nicholas Arnold; Becky Skinner; Jacob Simmering; Michael Eberlein; Alejandro P Comellas; Spyridon Fortis Journal: Respir Care Date: 2020-09-01 Impact factor: 2.258
Authors: Sytse F Oudkerk; Firdaus A A Mohamed Hoesein; F Cumhur Öner; Jorrit-Jan Verlaan; Pim A de Jong; Jonneke S Kuperus; Michael Cho; Merry-Lynn McDonald; David A Lynch; Edwin K Silverman; James D Crapo; Barry J Make; Katherine E Lowe; Elizabeth A Regan Journal: J Rheumatol Date: 2019-05-01 Impact factor: 4.666
Authors: M Bradley Drummond; Laurence Huang; Philip T Diaz; Gregory D Kirk; Eric C Kleerup; Alison Morris; William Rom; Michael D Weiden; Enxu Zhao; Bruce Thompson; Kristina Crothers Journal: AIDS Date: 2015-08-24 Impact factor: 4.177
Authors: Monica M Vasquez; Duane L Sherrill; Tricia D LeVan; Wayne J Morgan; Joseph H Sisson; Stefano Guerra Journal: Alcohol Date: 2017-09-01 Impact factor: 2.405
Authors: Chitra K Rao; Charity G Moore; Eugene Bleecker; William W Busse; William Calhoun; Mario Castro; Kian Fan Chung; Serpil C Erzurum; Elliot Israel; Douglas Curran-Everett; Sally E Wenzel Journal: Chest Date: 2013-04 Impact factor: 9.410